Labcorp Holdings Inc. LH
Set alert
At close
Pre-market · Nov 3, 8:14 AM ET
- YTD
- +41.74%
- 1 year
- +37.91%
- Open
- 361.54
- Prev close
- 361.39
- Mkt cap
- 28.87B
- Vol
- 1.09M
- Avg vol
- 716.85K
- EPS
- 12.20
- P/E
- 29.15
- Div yield
- 0.78%
More statistics
- Low
- 353.68
- High
- 362.91
- Forward P/E
- 18.16
- Beta
- 0.83
- Short ratio
- 3.39
- Inst. own
- 101.46%
- Dividend
- 2.88
- Ex-div date
- Nov 23, 2026
- Earnings
- Feb 16, 2027
- 50-d avg
- 323.22
- 200-d avg
- 287.55
- 1y target
- 382.25
5D chart
Events in this range
- Oct 28, 2026Earnings: 4.78; estimate 4.64; surprise 3.02%
- Oct 29, 2026Rating: Baird · Outperform → Outperform
- Oct 29, 2026Rating: Truist Securities · Buy → Buy
- Oct 29, 2026Rating: Barclays · Equal-Weight → Equal-Weight
- Oct 29, 2026Rating: UBS · Buy → Buy
Signals (113)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Nov 2, 3:55 PM | 16 hours ago |
| SMA: Bullish | Nov 2, 3:30 PM | 17 hours ago |
| SMA: Bearish | Nov 2, 3:25 PM | 17 hours ago |
| SMA: Bullish | Nov 2, 3:00 PM | 17 hours ago |
| SMA: Bearish | Nov 2, 2:55 PM | 17 hours ago |
| SMA: Bullish | Nov 2, 2:50 PM | 17 hours ago |
| SMA: Bullish | Nov 2, 2:45 PM | 17 hours ago |
| MACD: Buy Signal | Nov 2, 2:45 PM | 17 hours ago |
| MACD: Sell Signal | Nov 2, 2:00 PM | 18 hours ago |
| SMA: Bearish | Nov 2, 1:45 PM | 18 hours ago |
| SMA: Bearish | Nov 2, 1:40 PM | 18 hours ago |
| SMA: Bullish | Nov 2, 1:10 PM | 19 hours ago |
| SMA: Bullish | Nov 2, 12:55 PM | 19 hours ago |
| SMA: Bearish | Nov 2, 12:45 PM | 19 hours ago |
| SMA: Bullish | Nov 2, 12:20 PM | 20 hours ago |
| MACD: Buy Signal | Nov 2, 12:10 PM | 20 hours ago |
| RSI: Oversold | Nov 2, 11:55 AM | 20 hours ago |
| SMA: Bearish | Nov 2, 10:50 AM | 21 hours ago |
| SMA: Bullish | Nov 2, 10:45 AM | 21 hours ago |
| SMA: Bearish | Nov 2, 10:00 AM | 22 hours ago |
Newest 20 of 113.
News
3 days ago zacks.com
Labcorp Holdings (LH) is a Top-Ranked Value Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
4 days ago defenseworld.net
Labcorp Q3 Earnings Call Highlights
Labcorp (NYSE: LH) reported third-quarter 2026 revenue growth, margin expansion and double-digit adjusted earnings-per-share growth, prompting the laboratory services company to raise the midpoint of…
-
4 days ago benzinga.com
UBS Maintains Buy on Labcorp Holdings, Raises Price Target to $420
UBS analyst Kevin Caliendo maintains Labcorp Holdings (NYSE:LH) with a Buy and raises the price target from $380 to $420.
-
4 days ago benzinga.com
Barclays Maintains Equal-Weight on Labcorp Holdings, Raises Price Target to $380
Barclays analyst Luke Sergott maintains Labcorp Holdings (NYSE:LH) with a Equal-Weight and raises the price target from $330 to $380.
-
4 days ago benzinga.com
Truist Securities Maintains Buy on Labcorp Holdings, Raises Price Target to $395
Truist Securities analyst David Macdonald maintains Labcorp Holdings (NYSE:LH) with a Buy and raises the price target from $365 to $395.
5 days ago seekingalpha.com
Labcorp Holdings: The Optimism May Be Going Overboard (Rating Downgrade)
Labcorp Holdings raised guidance, triggering a sharp stock price rally. I view LH as a compelling long-term growth story, but current valuation is stretched. The price-earnings ratio approaching 20…
-
5 days ago benzinga.com
Baird Maintains Outperform on Labcorp Holdings, Raises Price Target to $396
Baird analyst Eric Coldwell maintains Labcorp Holdings (NYSE:LH) with a Outperform and raises the price target from $361 to $396.
5 days ago seekingalpha.com
Labcorp Holdings Inc. (LH) Q3 2026 Earnings Call Transcript
Labcorp Holdings Inc. (LH) Q3 2026 Earnings Call Transcript
5 days ago benzinga.com
Labcorp Targets Margin Growth, Absorbs Policy Headwinds
Labcorp Holdings (NYSE:LH) stock is trading at a 52-week high after the company reported upbeat third-quarter earnings and raised its fiscal outlook.
5 days ago benzinga.com
Labcorp Targets Margin Growth, Absorbs Policy Headwinds
Labcorp shares reach a 52-week high after beating Q3 consensus estimates. The company raises fiscal 2026 guidance and expands diagnostic acquisitions.
5 days ago marketbeat.com
Labcorp Q3 Earnings Call Highlights
Labcorp NYSE: LH reported third-quarter 2026 revenue growth, margin expansion and double-digit adjusted earnings-per-share growth, prompting the laboratory services company to raise the midpoint of…
5 days ago benzinga.com
SK Hynix, Vertiv Rescue AI Trade As Oil Tops $102 Before Fed: Stock Market Today
Stock market today: SK hynix and Vertiv rally on AI-driven results as oil tops $102 on Iran fears and the 10-year yield tops 5% before the Fed; SMH gains.
5 days ago zacks.com
LH Stock Rises on Q3 Earnings and Revenue Beat, '26 View Up
Labcorp shares rise as Q3 earnings and revenues beat estimates, both segments deliver growth, margins expand and the company raises its 2026 financial outlook.
5 days ago benzinga.com
Vertiv, Evercore, Brinker, GE HealthCare And Other Big Stocks Moving Higher On Wednesday
U.S. stocks mixed; Dow gained ~100 points. Vertiv jumped 13.3% on strong results and raised guidance; Ultralife soared 145.8% on buyout news.
5 days ago zacks.com
Compared to Estimates, Labcorp (LH) Q3 Earnings: A Look at Key Metrics
Although the revenue and EPS for Labcorp (LH) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall…
5 days ago benzinga.com
Labcorp Hldgs Q3 2026 Earnings Call Transcript
Labcorp Hldgs (NYSE:LH) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you…
6 days ago zacks.com
Labcorp Holdings (LH) Q3 Earnings and Revenues Surpass Estimates
Labcorp Holdings (LH) came out with quarterly earnings of $4.78 per share, beating the Zacks Consensus Estimate of $4.65 per share. This compares to earnings of $4.18 per share a year ago.
-
6 days ago benzinga.com
Labcorp Holdings Raises FY2026 Adj EPS Guidance from $18.10-$18.55 to $18.30-$18.70 vs $18.36 Est; Raises FY2026 Sales Guidance from $14.710B-$14.827B to $14.779B-$14.887B vs $14.749B Est
Labcorp Holdings (NYSE:LH) raises FY2026 Adj EPS guidance from $18.10-$18.55 to $18.30-$18.70 vs $18.36 analyst estimate. Raises FY2026 sales outlook from $14.710 billion-$14.827 billion to $14.779…
-
6 days ago benzinga.com
Laboratory Corp Q3 Adj. EPS $4.78 Beats $4.66 Estimate, Sales $3.810B Beat $3.759B Estimate
Laboratory Corp (NYSE:LH) reported quarterly earnings of $4.78 per share which beat the analyst consensus estimate of $4.66 by 2.58 percent. This is a 14.35 percent increase over earnings of $4.18…
6 days ago prnewswire.com
Labcorp Reports Strong 2026 Third Quarter Results; Raises Full Year 2026 Guidance
Results from operations for third quarter 2026 versus third quarter 2025: Revenue: $3.81 billion vs. $3.56 billion, up 6.9% Diluted EPS: $3.22 vs.
6 days ago zacks.com
Waters & Labcorp Expand Access to FDA-Approved HPV Screening Tests
WAT partners with Labcorp to expand access to FDA-approved HPV testing by late 2026, potentially boosting diagnostics adoption and cervical cancer screening.
-
1 week ago benzinga.com
Waters And Labcorp To Expand Access To BD Onclarity HPV Assay
Labcorp intends to be the first commercial laboratory to offer FDA-approved HPV testing with the BD Onclarity™ HPV Assay across clinician-collected and self-collected screening options in clinic,…
-
1 week ago benzinga.com
Charles River Laboratories Announces Research Collaboration Agreement With FDA And Labcorp For Developing Sensitive Screening Tools To Quantify And Rank Abuse Potential Of New Drugs
Joint research effort seeks to improve abuse potential assessment tools to support drug development and public health decision-makingCharles River Laboratories International, Inc. (NYSE:CRL) today…
1 week ago benzinga.com
Myriad Genetics Offloads Struggling Prenatal Unit for $210 Million to Labcorp
Labcorp will purchase Myriad Genetics' prenatal testing business for $210 million in cash, projecting $160 million in year-one revenue.
-
2 weeks ago benzinga.com
Myriad Genetics To Sell Its Prenatal Health Testing Business, Including Prequel, Foresight, SneakPeek And FirstGene Tests, To Labcorp For $210M In Cash Plus Inventory Value
When complete, the transaction is expected to provide more patients and physicians with expanded access to Labcorp’s comprehensive, high-quality laboratory services, convenient patient service center…
2 weeks ago benzinga.com
OPKO Health Sheds Diagnostics Businesses in Major Labcorp Deal
OPKO Health jumps 18% and Labcorp trades higher as LH acquires BioReference Health assets in an $872M deal.
-
2 weeks ago benzinga.com
UPDATE: Labcorp Agrees To Acquire Select Assets Of OPKO Health's BioReference Health Subsidiary For $722M In Cash, Up To Additional $150M In Earnout On Revenue
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (NASDAQ:OPK), a multinational biopharmaceutical company, announced today that they have…
-
2 weeks ago benzinga.com
Labcorp Agrees To Acquire Select Assets Of OPKO Health's BioReference Health Subsidiary For $722M In Cash, Up To Additional $150M In Earnout On Revenue
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (NASDAQ:OPK), a multinational biopharmaceutical company, announced today that they have…
-
1 month ago benzinga.com
Labcorp Reaffirms 2026–2029 Long-Term Outlook Following CMS Preliminary Medicare Payment Rate Release; Expects Compound Annual Adj EPS Growth Of 8.5%-11.5% In 2026-2029
On September 21, 2026, the Centers for Medicare & Medicaid Services ("CMS") released preliminary Clinical Laboratory Fee Schedule payment rates applicable from 2027 through 2029 pursuant to the…
1 month ago benzinga.com
Ericsson, Lexeo Therapeutics And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. stock futures were mixed. Ericsson fell 4.3% after a Morgan Stanley downgrade; Quest Diagnostics, Rambus and others also declined premarket.
-
1 month ago benzinga.com
Truist Securities Maintains Buy on Labcorp Holdings, Raises Price Target to $365
Truist Securities analyst David Macdonald maintains Labcorp Holdings (NYSE:LH) with a Buy and raises the price target from $350 to $365.
1 month ago benzinga.com
Deal Dispatch: Bending Spoons Acquires Miro For $1.35B, Kinetik Up For Sale, LIV Golf Bankruptcy
Read this week's top deal updates, including Bending Spoons' Miro deal, Chime's Stride Bank purchase, and the LIV Golf bankruptcy.
-
1 month ago benzinga.com
UBS Maintains Buy on Labcorp Holdings, Raises Price Target to $380
UBS analyst Kevin Caliendo maintains Labcorp Holdings (NYSE:LH) with a Buy and raises the price target from $361 to $380.
-
1 month ago benzinga.com
Barclays Maintains Equal-Weight on Labcorp Holdings, Raises Price Target to $330
Barclays analyst Luke Sergott maintains Labcorp Holdings (NYSE:LH) with a Equal-Weight and raises the price target from $320 to $330.
1 month ago benzinga.com
Labcorp Bets Big on AI, Specialty Testing to Drive Growth Through 2029
Labcorp shares its strategic priorities and reaffirms 2026 guidance at its Investor Day, forecasting steady revenue growth through 2029.
-
1 month ago benzinga.com
Labcorp Provides Long-Term Outlook Through 2029, With 5%-8% Revenue CAGR And 8.5%-11.5% Adj EPS CAGR
Reaffirms full-year 2026 guidanceProvides long-term outlook through 2029, with compound annual revenue growth of 5% to 8% and compound annual adjusted earnings per share (EPS) growth of 8.5% to…
-
1 month ago benzinga.com
Labcorp Holdings Affirms FY2026 Adj EPS Guidance of $18.10-$18.55 vs $18.01 Est; Affirms FY2026 Sales Guidance of $14.710B-$14.827B vs $14.707B Est
Labcorp Holdings (NYSE:LH) affirms FY2026 Adj EPS guidance from $18.10-$18.55 to $18.10-$18.55 vs $18.01 analyst estimate. Affirms FY2026 sales outlook from $14.710 billion-$14.827 billion to $14.710…
-
1 month ago benzinga.com
Labcorp Acquires MLM Medical Labs; Financial Terms Not Disclosed
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the acquisition of MLM Medical Labs (MLM), a leading global central and specialty laboratory…
-
2 months ago benzinga.com
Labcorp To Offer Elecsys pTau-217 Test Following Clearance By FDA
Elecsys® pTau-217 is the first and only FDA-cleared single-biomarker blood test to both rule in and rule out amyloid pathology across specialty and primary care settingsMeasures phosphorylated Tau…
-
2 months ago benzinga.com
Labcorp And NACHC Announce Strategic Alliance To Support Practice Improvement And Advance Community Health Initiatives Across Community Health Center Network
Collaboration will support leadership development, practice improvement and innovation across the nation's Community Health CentersBURLINGTON, N.C. and BETHESDA, Md., Aug. 18, 2026 /PRNewswire/ --…
-
3 months ago benzinga.com
Labcorp Announces Availability of Roche's Ventana Pten RxDx Assay, First Immunohistochemistry Companion Diagnostic Test Approved By FDA To Determine Pten Protein Loss In Prostate Adenocarcinoma Patients
The assay helps identify patients who may be eligible for treatment with AstraZeneca's TRUQAP® (capivasertib) in combination with abiraterone acetate and prednisone.
-
3 months ago benzinga.com
JP Morgan Maintains Overweight on Labcorp Holdings, Raises Price Target to $360
JP Morgan analyst Lisa Gill maintains Labcorp Holdings (NYSE:LH) with a Overweight and raises the price target from $330 to $360.
-
3 months ago benzinga.com
Morgan Stanley Maintains Overweight on Labcorp Holdings, Raises Price Target to $338
Morgan Stanley analyst Ricky Goldwasser maintains Labcorp Holdings (NYSE:LH) with a Overweight and raises the price target from $308 to $338.
-
3 months ago benzinga.com
Truist Securities Maintains Buy on Labcorp Holdings, Raises Price Target to $350
Truist Securities analyst David Macdonald maintains Labcorp Holdings (NYSE:LH) with a Buy and raises the price target from $320 to $350.
-
3 months ago benzinga.com
Barclays Maintains Equal-Weight on Labcorp Holdings, Raises Price Target to $320
Barclays analyst Jack Meehan maintains Labcorp Holdings (NYSE:LH) with a Equal-Weight and raises the price target from $290 to $320.
-
3 months ago benzinga.com
Labcorp Holdings Raises FY2026 Adj EPS Guidance from $17.70-$18.35 to $18.10-$18.55 vs $18.01 Est; Raises FY2026 Sales Guidance from $14.650B-$14.800B to $14.710B-$14.827B vs $14.707B Est
Labcorp Holdings (NYSE:LH) raises FY2026 Adj EPS guidance from $17.70-$18.35 to $18.10-$18.55 vs $18.01 analyst estimate. Raises FY2026 sales outlook from $14.650 billion-$14.800 billion to $14.710…
-
3 months ago benzinga.com
Laboratory Corp Q2 Adj. EPS $4.99 Beats $4.78 Estimate, Sales $3.731B Beat $3.711B Estimate
Laboratory Corp (NYSE:LH) reported quarterly earnings of $4.99 per share which beat the analyst consensus estimate of $4.78 by 4.39 percent. This is a 14.71 percent increase over earnings of $4.35…
-
3 months ago benzinga.com
B of A Securities Maintains Buy on Labcorp Holdings, Raises Price Target to $320
B of A Securities analyst Michael Ryskin maintains Labcorp Holdings (NYSE:LH) with a Buy and raises the price target from $300 to $320.
-
3 months ago benzinga.com
Baird Maintains Outperform on Labcorp Holdings, Raises Price Target to $338
Baird analyst Eric Coldwell maintains Labcorp Holdings (NYSE:LH) with a Outperform and raises the price target from $335 to $338.
-
4 months ago benzinga.com
Labcorp Announces Nationwide Availability Of ColoSense, Its RNA-Based, At-Home Colorectal Cancer Screening Test
First FDA-approved, at-home screening test that uses RNA technology to detect biomarkers associated with colorectal cancer and advanced adenomasDesigned to reduce common barriers to at-home screening…